Spinogenix

Executive Summary

Spinogenix is a preclinical-stage neuroscience company developing small molecule therapeutics that promote synaptic regeneration and repair, targeting the fundamental loss of neuronal connections underlying neurodegenerative diseases. Founded in 2018 and based in San Diego, the company's novel approach aims to directly enhance synapse structure and function, potentially offering disease-modifying benefits for conditions such as Alzheimer's, Parkinson's, and other synaptic disorders. While still in early development, Spinogenix's strategy addresses a critical unmet need in neurodegeneration, where current therapies largely manage symptoms rather than halt or reverse disease progression. The company's platform has the potential to differentiate from competitors by focusing on synaptic repair rather than amyloid or tau clearance. However, as a private preclinical entity, Spinogenix faces typical development risks including funding requirements, regulatory hurdles, and the need for clinical validation. The next 12-24 months are likely to be pivotal as the company advances its lead candidates toward the clinic and seeks to establish proof-of-concept in animal models.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate IND-enabling studies completion40% success
• TBDPartnership or licensing deal for platform technology25% success
• Q2 2027Series A or follow-on financing round50% success